[go: up one dir, main page]

EP1250091B1 - Colorants hydrophiles a base de cyanine - Google Patents

Colorants hydrophiles a base de cyanine Download PDF

Info

Publication number
EP1250091B1
EP1250091B1 EP01904882A EP01904882A EP1250091B1 EP 1250091 B1 EP1250091 B1 EP 1250091B1 EP 01904882 A EP01904882 A EP 01904882A EP 01904882 A EP01904882 A EP 01904882A EP 1250091 B1 EP1250091 B1 EP 1250091B1
Authority
EP
European Patent Office
Prior art keywords
och
conh
nhco
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01904882A
Other languages
German (de)
English (en)
Other versions
EP1250091A4 (fr
EP1250091A1 (fr
Inventor
Samuel I. Achilefu
Raghavan Rajagopalan
Richard B. Dorshow
Joseph E. Bugaj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/484,319 external-priority patent/US6180086B1/en
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of EP1250091A1 publication Critical patent/EP1250091A1/fr
Publication of EP1250091A4 publication Critical patent/EP1250091A4/fr
Application granted granted Critical
Publication of EP1250091B1 publication Critical patent/EP1250091B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes

Definitions

  • This invention relates generally to compositions of cyanine dye bioconjugates with bioactive molecules for diagnosis and therapy, particularly, for visualization and detection of tumors.
  • Cyanine dyes with intense absorption and emission in the near-infrared (NIR) region are particularly useful because biological tissues are optically transparent in this region ( B. C. Wilson, Optical properties of tissues. Encyclopedia of Human Biology, 1991, 5, 587-597 ).
  • NIR near-infrared
  • indocyanine green which absorbs and emits in the NIR region, has been used for monitoring cardiac output, hepatic functions, and liver blood flow ( Y-L. He, et al., Measurement of blood volume using indocyanine green measured with pulse-spectrometry: lts reproducibility and reliability.
  • Critical Care Medicine 1998, 26(8), 1446-1451 ; J.
  • cyanine dye derivatives A major drawback in the use of cyanine dye derivatives is the potential for hepatobiliary toxicity resulting from the rapid clearance of these dyes by the liver ( G. R. Cherrick, et al., Indocyanine green: Observations on its physical properties, plasma decay, and hepatic extraction. J. Clinical Investigation, 1960, 39, 592-600 ). This is associated with the tendency of cyanine dyes in solution to form aggregates, which could be taken up by Kupffer cells in the liver.
  • the invention is directed to compositions, and methods of preparing the compositions, of low molecular weight biomolecule-dye conjugates to enhance tumor detection.
  • inventive compositions preserve the fluorescence efficiency of the dye molecules, do not aggregate in solution, form starburst dendrimers, are capable of absorbing or emitting light in the near infrared region (beyond 800 nm), and can be rendered tissue-specific.
  • the inventive composition comprises cyanine dyes of general formula 1 wherein W 3 and X 3 may be the same or different and are selected from the group consisting of -CR 1 R 2 , -O-, -NR 3 , -S-, and -Se; Y 3 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 ) a -NHCO-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -NHCO-Bm, -(CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) c
  • the inventive composition comprises cyanine dyes of general formula 2 wherein W 4 and X 4 may be the same or different and are selected from the group consisting of -CR 1 R 2 , -O-, -NR 3 , -S-, and -Se; Y 4 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 ) a -NHCO-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -NHCO-Bm, -(CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) c
  • the inventive composition comprises cyanine dyes of general formula 3 wherein W 5 and X 5 may be the same or different and are selected from the group consisting of -CR 1 R 2 , -0-, -NR 3 , -S-, and -Se; Y 5 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 ) a -NHCO-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -NHCO-Bm, -(CH 2 ) a N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) c -NHCO-Bm, -(CH 2 ) a -N(R 3 )-CH 2 )-CH 2
  • inventive composition comprises cyanine dyes of general formula 4 wherein W 6 and X 6 may be the same or different and are selected from the group consisting of -CR 1 R 2 , -O-, -NR 3 , -S-, and -Se; Y 6 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 ) a -NHCO-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -NHCO-Bm, -(CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) b -CONH-Bm, (CH 2 ) a -N(R 3 )-(CH 2 ) c
  • novel compositions of the present invention comprising dyes of formulas 1 to 4 offer significant advantages over those currently described in the art.
  • inventive dyes form starburst dendrimers which prevent aggregation in solution by preventing intramolecular and intermolecular ordered hydrophobic interactions, and have multiple attachment sites proximal to the dye chromophore for ease of forming bioactive molecules.
  • the presence of rigid and extended chromophore backbone enhances their fluorescence quantum yield and extends their maximum absorption beyond 800 nm. Conjugation of biomolecules to these dyes is readily achievable.
  • the inventive bioconjugates of the present invention also exploit the symmetric nature of the cyanine and indocyanine dye structures by incorporating one to ten receptor targeting groups in close proximity to each other, such that the receptor binding can be greatly enhanced due to a cooperative effect. Accordingly, several cyanine dyes containing one or more targeting domains have been prepared and tested in vivo for biological activity.
  • inventive dye-bioconjugates of formulas 1 to 4 are useful for various biomedical applications. These include, but are not limited to, tomographic imaging of organs, monitoring of organ functions, coronary angiography, fluorescence endoscopy, detection, imaging, and therapy of tumors, laser assisted guided surgery, photoacoustic methods, and sonofluorescent methods.
  • novel dyes of the present invention are prepared according the methods well known in the art and are illustrated in FIGS. 1-5 .
  • the inventive bioconjugates have the Formula 1, wherein W 3 and X 3 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a CO 2 H)CH 3 , -C((CH 2 ) a CO 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , -C((CH 2 ) a NH 2 ) 2 , C((CH 2 ) a NR 3 R 4 ) 2 , -NR 3 , and -S-; Y 3 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 )
  • the inventive bioconjugates have the general Formula 2, wherein W 4 and X 4 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a CO 2 H)CH 3 , -C((CH 2 ) a CO 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , C((CH 2 ) a NH 2 ) 2 , -C((CH 2 ) a NR 3 R 4 ) 2 , -NR 3 , and -S-; Y 4 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2
  • the inventive bioconjugates have the general Formula 3, wherein W 5 and X 5 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a CO 2 H)CH 3 , -C((CH 2 ) a CO 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , -C((CH 2 ) a NH 2 ) 2 , -C((CH 2 ) a NR 3 R 4 ) 2 , -NR 3 , and -S-; Y 5 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -CCH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(
  • the inventive bioconjugates have the general Formula 4, wherein W 6 and X 6 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a CO 2 H)CH 3 , - C((CH 2 ) a CO 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , -C((CH 2 ) a NH 2 ) 2 , C((CH 2 ) a NR 3 R 4 ) 2 , -NR 3 , and -S-; Y 6 is selected from the group consisting of -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2
  • This invention is also related to the method of preventing fluorescence quenching. It is known that cyanine dyes generally form aggregates in aqueous media, leading to fluorescence quenching. Where the presence of a hydrophobic core in the dyes leads to fluorescence quenching, the addition of a biocompatible organic solvent, such, as 1-50% dimethylsulfoxide (DMSO) for example, restored fluorescence by preventing aggregation and allowed in vivo organ visualization.
  • DMSO dimethylsulfoxide
  • the inventive dye-biomolecule conjugates are used for optical tomographic, endoscopic, photoacoustic and sonofluorescent applications for the detection and treatment of tumors and other abnormalities.
  • Dye-biomolecule conjugates are also used for localized therapy. This may be accomplished by attaching a porphyrin or other photodynamic therapy agent to a bioconjugate, shining light of an appropriate wavelength to activate the agent, and detecting and/or treating the abnormality.
  • the inventive conjugates can also be used for the detection of the presence of tumors and other abnormalities by monitoring the blood clearance profile of the conjugates, for laser assisted guided surgery for the detection of small micrometastases of, e.g., somatostatin subtype 2 (SST-2) positive tumors, upon laparoscopy, and for diagnosis of atherosclerotic plaques and blood clots.
  • SST-2 somatostatin subtype 2
  • compositions of the invention can be formulated into diagnostic and therapeutic compositions for enteral or parenteral administration.
  • These compositions contain an effective amount of the dye along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
  • parenteral formulations advantageously contain the inventive agent in a sterile aqueous solution or suspension.
  • Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
  • Such solutions also may contain pharmaceutically acceptable buffers and, optionally, electrolytes such as sodium chloride.
  • Formulations for enteral administration may vary widely, as is well known in the art.
  • such formulations are liquids, which include an effective amount of the inventive agent in aqueous solution or suspension.
  • Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like.
  • Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
  • the diagnostic compositions are administered in doses effective to achieve the desired enhancement. Such doses may vary widely, depending upon the particular dye employed, the organs or tissues to be imaged, the imaging equipment being used, and the like.
  • the diagnostic compositions of the invention are used in the conventional manner.
  • the compositions may be administered to a patient, typically a warm-blooded animal, either systemically or locally to the organ or tissue to be imaged, and the patient is then subjected to the imaging procedure.
  • compositions and methods represent an important approach to the synthesis and use of novel cyanine and indocyanine dyes with a variety of photophysical and chemical properties.
  • the combination also represents an important approach to the use of small molecular targeting groups to image tumors by optical methods.
  • the invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the scope of the invention in any manner.
  • This compound was prepared as described in Example 1 except that 1,1,2-trimethylindole was used as the starting material.
  • This compound was prepared as described in Example 1 except that ⁇ -bromohexaoxyethyleneglycolpropiolic acid was used in place of bromopropanoic acid and the reaction was carried out in 1,2-dimethoxypropane.
  • the reaction mixture was partitioned between 100 ml of methylene chloride and 100 ml of saturated sodium bicarbonate solution. The layers were separated and the methylene chloride layer was again washed with 100 ml of saturated sodium bicarbonate solution. The combined aqueous layers were extracted twice with 25 ml of methylene chloride. The combined methylene chloride layers were washed with 1 00 ml of brine, and dried over magnesium sulfate. The methylene chloride was removed with aspirator vacuum at about 35°C, and the remaining dimethylformamide was removed with vacuum at about 45°C. The crude material was left on a vacuum line overnight at room temperature.
  • the ether solution was decanted and the oil was again triturated with a 100 ml portion of ether.
  • the ether was decanted and the combined ether solution was allowed to stand for about two hours to allow the triphenylphosphine oxide to crystallize.
  • the ether solution was decanted from the crystals and the solid was washed with 100 ml of ether.
  • the volume of the combined ether extracts was reduced with vacuum until a volume of about 25 ml was obtained. This was allowed to stand overnight at 0°C. Ether (10 ml) was added to the cold mixture, which was mixed.to suspend the solid.
  • the mixture was percolated through a column of 45 g of silica gel and eluted with ether, and 75 ml fractions were collected.
  • the fractions that contained product, as determined by thin layer chromatography, were pooled and the ether was removed with vacuum. This yielded 10.1 g of crude product.
  • the material was flash chromatographed on silica gel with hexane, changing to 9:1 hexane:ether.
  • the product-containing fractions were pooled and the solvents removed with vacuum. This yielded 7.4 g (57% yield) of pure product.
  • the hydroxy-indole compound is readily prepared by a known method ( P. L. Southwick et al., One pot Fischer synthesis of (2,3,3-trimethyl-3-H-indol-5-yl)-acetic acid derivatives as intermediates for fluorescent biolabels. Org. Prep. Proced. Int. Briefs, 1988, 20(3), 279-284 ).
  • the intermediate 2-chloro-1-formyl-3-hydroxymethylenecyclohexane was prepared as described in the literature ( G. A. Reynolds and K. H. Drexhage, Stable heptamethine pyrylium dyes that absorb in the infrared. J. Org. Chem., 1977, 42(5), 885-888 ).
  • Equal volumes (40 mL each) of dimethylformamide (DMF) and dichloromethane were mixed and the solution was cooled to -10°C in an acetone-dry ice bath. Under argon atmosphere, phosphorus oxychloride (40 mL) in dichloromethane was added dropwise to the cool DMF solution, followed by the addition of 10 g of cyclohexanone.
  • These dyes are prepared as described in Example 7. These dyes absorb in the infrared region.
  • the typical example shown in FIG. 5 has an estimated absorption maximum at 1036 nm.
  • Octreotate The procedure described below is for the synthesis of Octreotate.
  • the amino acid sequence of Octreotate is: D-Phe-Cys'-Tyr-D-Trp-Lys-Thr-Cys'-Thr (SEQ ID NO:1), wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids.
  • Other peptides of this invention were prepared by a similar procedure with slight modifications in some cases.
  • the octapeptide was prepared by an automated fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis using a commercial peptide synthesizer from Applied Biosystems (Model 432A SYNERGY Peptide Synthesizer).
  • the first peptide cartridge contained Wang resin pre-loaded with Fmoc-Thr on 25 ⁇ mole scale.
  • Subsequent cartridges contained Fmoc-protected amino acids with side chain protecting groups for the following amino acids: Cys(Acm), Thr(t-Bu), Lys(Boc), Trp(Boc) and Tyr(t-Bu).
  • the amino acid cartridges were placed on the peptide synthesizer and the product was synthesized from the C-to the N-terminal position.
  • the coupling reaction was carried out with 75 ⁇ moles of the protected amino acids in the presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-hydroxybenzotriazole (HOBt).
  • HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
  • HOBt N-hydroxybenzotriazole
  • the Fmoc protecting group was removed with 20% piperidine in dimethylformamide.
  • the thiol group was cyclized with thallium trifluoroacetate and the product was cleaved from the solid support with a cleavage mixture containing trifluoroacetic acid (85%):water (5%):phenol (5%):thioanisole (5%) for six hours.
  • the peptide was precipitated with t-butyl methyl ether and lyophilized with water:acetonitrile (2:3) mixture.
  • the peptide was purified by HPLC and analyzed with LC/MS.
  • Octreotide D-Phe-Cys'-Tyr-D-Trp-Lys-Thr-Cys'-Thr-OH (SEQ ID NO:2), wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids, was prepared by the same procedure.
  • Bombesin analogs were prepared by the same procedure except that cyclization with thallium trifluoroacetate was not needed. Side-chain deprotection and cleavage from the resin was carried out with 50 ⁇ L each of ethanedithiol, thioanisole and water, and 850 ⁇ L of trifluoroacetic acid. Two analogues were prepared: Gly-Ser-Gly-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (SEQ ID NO:3) and Gly-Asp-Gly-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (SEQ ID NO:4).
  • Cholecystokinin octapeptide analogs were prepared as described for Octreotate without the cyclization step. Three analogs were prepared: Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH 2 (SEQ ID NO:5); Asp-Tyr-Nie-Gly-Trp-Nle-Asp-Phe-NH 2 (SEQ ID NO:6); and D-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH 2 (SEQ ID NO:7), where Nle is norleucine.
  • a neurotensin analog D-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu (SEQ ID NO:8), was prepared as described for Octreotate without the cyclization step.
  • Octreotate was prepared as described in Example 9 but the peptide was not cleaved from the solid support and the N-terminal Fmoc group of Phe was retained. The thiol group was cyclized with thallium trifluoroacetate and the Phe was deprotected to liberate the free amine. Bisethylcarboxymethylindocyanine dye (53 mg, 75 ⁇ moles) was added to an activation reagent consisting of a 0.2 M solution of HBTU/HOBt in DMSO (375 ⁇ L), and 0.2 M solution of diisopropylethylamine in DMSO (375 ⁇ L).
  • the activation was complete in about 30 minutes and the resin-bound peptide (25 ⁇ moles) was added to the dye.
  • the coupling reaction was carried out at room temperature for three hours. The mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF. After drying the green residue, the peptide was cleaved from the resin and the side chain protecting groups were removed with a mixture of 85% trifluoroacetic acid, 2.5% water, 2.5% thioanisole and 2.5% phenol.
  • the resin was filtered and cold t-butyl methyl ether (MTBE) was used to precipitate the dye-peptide conjugate, which was dissolved in an acetonitrile:water (2:3) mixture and lyophilized.
  • MTBE cold t-butyl methyl ether
  • the product was purified by HPLC to give the monoOctreotate-Bisethylcarboxymethylindocyanine dye (Cytate 1, 80%) and the bis Octreotate-Bisethylcarboxymethylindocyanine dye (Cytate 2, 20%).
  • the monoOctreotate conjugate is obtained almost exclusively (>95%) over the bis conjugate by reducing the reaction time to two hours. However, this also leads to incomplete reaction, and the free Octreotate must be carefully separated from the dye conjugate in order to avoid saturation of the receptors by the non-dye conjugated peptide.
  • Octreatate-bispentylcarboxymethylindocyanine dye was prepared as described above with some modifications.
  • Bispentylcarboxymethylindocyanine dye (60 mg, 75 ⁇ moles) was added to an activation reagent consisting of a 0.2 M solution of HBTU/HOBt in DMSO (400 ⁇ L), and a 0.2 M solution of diisopropylethylamine in DMSO (400 ⁇ L).
  • the activation was complete in about 30 minutes and the resin-bound peptide (25 ⁇ moles) was added to the dye.
  • the reaction was carried out at room temperature for three hours. The mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF.
  • the peptide was cleaved from the resin and the side chain protecting groups were removed with a mixture of 85% trifluoroacetic acid, 2.5% water, 2.5% thioanisole and 2.5% phenol.
  • the resin was filtered and cold t-butyl methyl ether (MTBE) was used to precipitate the dye-peptide conjugate, which was dissolved in an acetonitrile:water (2:3) mixture and lyophilized.
  • MTBE cold t-butyl methyl ether
  • the product was purified by HPLC to give Octreotate-1,1,2-trimethyl-[1 H]-benz[e]indole propanoic acid conjugate (10%), monoOctreotate-bispentylcarboxymethylindocyanine dye (Cytate 3, 60%) and bisOctreotate-bispentylcarboxymethylindocyanine dye (Cytate 4, 30%).
  • the dye-peptide conjugates are sparingly soluble in water and require the addition of solubilizing agents or co-solvents.
  • Addition of 1-20% aqueous ethanol to the conjugates partially quenched the fluorescence intensity in vitro and the fluorescence was completely quenched in vivo (the conjugate was not detected by the charge coupled device (CCD) camera).
  • Addition of 1-50% of DMSO either re-established or increased the fluorescence intensity of the conjugates in vitro and in vivo. The dye fluorescence remained intense for over one week.
  • the DMSO formulations were well tolerated by experimental animals used for this invention.
  • a non-invasive in vivo fluorescence imaging apparatus was employed to assess the efficacy of contrast agents developed for tumor detection in animal models.
  • a LaserMax Inc. laser diode of nominal wavelength 780 nm and nominal power of 40 mW was used.
  • the detector was a Princeton Instruments model RTE/CCD-1317-K/2 CCD camera with a Rodenstock 10 mm F2 lens (stock #542.032.002.20) attached.
  • An 830 nm interference lens (CVI Laser Corp., part # F10-830-4-2) was mounted in front of the CCD input lens such that only emitted fluorescent light from the contrast agent was imaged.
  • an image of the animal was taken pre-injection of contrast agent. This image was subsequently subtracted (pixel by pixel) from the post injection images.
  • the background subtraction was never done once the animal had been removed from the sample area and returned at a later time for images taken several hours post injection.
  • DSL 6A tumors were induced in male Lewis rats in the left flank area by the introduction of material from a solid (donor) implant, and the tumors were palpable in approximately 14 days.
  • the animals were anesthetized with xylazine: ketamine: acepromazine, 1.5: 1.5: 0.5 at 0.8 mL/kg via intramuscular injection.
  • the area of the tumor (left flank) was shaved to expose the tumor and the surrounding surface area.
  • a 21 gauge butterfly equipped with a stopcock and two syringes containing heparinized saline was placed into the later tail vein of the rat. Patency of the vein was checked prior to administration of the ICG via the butterfly apparatus.
  • Each animal received 500 ⁇ L of a 0.42 mg/mL solution of ICG in water.
  • FIGS. 7A-B are tumor images at two minutes ( FIG. 7A ) and 30 minutes ( FIG. 7B ) post bolus injection of a 0.5 mL aqueous solution of ICG (5.4 ⁇ m).
  • the Figures are false color images of fluorescent intensity measured at the indicated times, with images constrained to the tumor and a small surrounding area. As is shown, the dye intensity in the tumor is considerably diminished 30 minutes post-ICG injection.
  • FIGS. 7C-D are images of a rat with an induced prostatic carcinoma tumor (R3327-H) imaged at two minutes ( FIG. 7C ) and 30 minutes ( FIG. 7D ) post injection.
  • the Figures are false color images of fluorescent intensity measured at the indicated times, with images constrained to the tumor and a small surrounding area. As is shown, the dye intensity in the tumor is considerably diminished 30 minutes post-ICG injection.
  • FIGS. 7E-F are images of a rat with an induced pancreatic acinar carcinoma ( CA20948 ) expressing the SST-2 receptor imaged at two minutes ( FIG. 7E ) and 30 minutes ( FIG. 7F ) post injection.
  • the Figures are false color images of fluorescent intensity measured at the indicated times, with images constrained to the tumor and a small surrounding area. As is shown, the dye intensity in the tumor is considerably diminished and almost absent 30 minutes post-ICG injection.
  • Example 12 The imaging apparatus and the procedure used are described in Example 12, except that each animal received 500 ⁇ l of a 1.0 mg/mL solution of Cytate 1 solution of 25% dimethylsulfoxide in water.
  • Rat pancreatic acinar carcinoma expressing the SST-2 receptor ( CA20948 ) were induced by solid implant technique in the left flank area, and palpable masses were detected 24 days post implant. Images were obtained at various times post injection. Uptake into the tumor was seen at two minutes but was not maximal until about five minutes.
  • FIGS. 8A-B show a comparison of the uptake of ICG and Cytate 1 at 45 minutes in rats with the CA20948 tumor cell line. By 45 minutes the ICG has mostly cleared ( FIG. 8A ) whereas the Cytate 1 is still intense ( FIG. 8B ). This dye fluorescence remained intense in the tumor for several hours post-injection.
  • ICG indocyanine green
  • the first two tumor lines are not as highly vascularized as CA20948 , which is also rich in somatostatin (SST-2) receptors. Consequently, the detection and retention of a dye in this tumor model is a good index of receptor-mediated specificity.
  • Octreotate is known to target somatostatin (SST-2) receptors, hence, cyano-Octreotates (Cytate 1 and Cytate 2) were prepared. Cytate 1 was evaluated in the CA20948 Lewis rat model. Using the CCD camera apparatus, localization of this dye was observed in the tumor (indicated by arrow) at 45 minutes post injection ( FIG. 9A ). At 27 hours post injection, the animal was again imaged ( FIG. 9B ). Tumor visualization was easily observed (indicated by arrow), showing specificity of this agent for the SST-2 receptors present in the CA20948 tumor line.
  • the AR42-J cell line is derived from exocrine rat pancreatic acinar carcinoma. It can be grown in continuous culture or maintained in vivo in athymic nude mice; SCID mice, or in Lewis rats. This cell line is particularly attractive for in vitro receptor assays, as it is known to express a variety of hormone receptors including cholecystokinin (CCK), epidermal growth factor (EGF), pituitary adenylate cyclase activating peptide (PACAP), somatostatin (SST-2) and bombesin.
  • CCK cholecystokinin
  • EGF epidermal growth factor
  • PACAP pituitary adenylate cyclase activating peptide
  • SST-2 somatostatin
  • FIG. 11 is an image of bombesinate in an AR42-J tumor-bearing rat, as described in Example 16, at 22 hours post injection of bombesinate. As shown in FIG. 11 , specific localization of the bioconjugate in the tumor (indicated by arrow) was observed.
  • a laser of appropriate wavelength for excitation of the dye chromophore was directed into one end of a fiber optic bundle and the other end was positioned a few millimeters from the ear of a rat.
  • a second fiber optic bundle was also positioned near the same ear to detect the emitted fluorescent light and the other end was directed into the optics and electronics for data collection.
  • An interference filter (IF) in the collection optics train was used to select emitted fluorescent light of the appropriate wavelength for the dye chromophore.
  • Sprague-Dawley or Fischer 344 rats were used in these studies.
  • the animals were anesthetized with urethane administered via intraperitoneal injection at a dose of 1.35 g/kg body weight.
  • a 21 gauge butterfly with 12" tubing was placed in the lateral tail vein of each animal and flushed with heparinized saline.
  • the animals were placed on a heating pad and kept warm throughout the entire study.
  • the lobe of the left ear was affixed to a glass microscope slide to reduce movement and vibration.
  • Incident laser light delivered from the fiber optic was centered on the affixed ear. Data acquisition was then initiated, and a background reading of fluorescence was obtained prior to administration of the test agent.
  • the peptide-dye conjugate was administered to the animal through a bolus injection, typically 0.5 to 2.0 mL, in the lateral tail vein. This procedure was repeated with several dye-peptide conjugates in normal and tumor-bearing rats. Representative profiles as a method to monitor blood clearance of the peptide-dye conjugate in normal and tumor-bearing animals are shown in FIGS. 12 to 16 . The data were analyzed using a standard sigma plot software program for a one-compartment model.
  • FIG. 12 shows the clearance profile of Cytate 1 from the blood of a normal rat monitored at 830 nm after excitation at 780 nm.
  • FIG. 13 shows the clearance profile of Cytate 1 from the blood of a pancreatic tumor ( CA20948 )-bearing rat also monitored at 830 nm after excitation at 780 nm.
  • FIG. 14 shows the clearance profile of Cytate 2 from the blood of a normal rat
  • FIG. 15 shows the clearance profile of Cytate 2 from the blood of a pancreatic tumor ( CA20948 )-bearing rat, monitored at 830 nm after excitation at 780 nm.
  • FIG. 16 shows the clearance profile of Cytate 4 from the blood of a normal rat monitored at 830 nm after excitation at 780 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)

Claims (21)

  1. Composé de formule
    Figure imgb0021
     où W3 et X3 sont choisis indépendamment l'un de l'autre parmi -CR1R2, -O-, -NR3, - S-, et -Se ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-N(R3)-(CH2)b-CONH-Bm, (CH2)a-N(R3)-(CH2)c-NHCO-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-N(R)-CH2-(CH2OCH2)b-CH2-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, -(CH2)a-N(R3)-(CH2)b-CONH-Dm, (CH2)a-N(R3)-(CH2)c-NHCO-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Dm, -CH2(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi -O-, -S-, -Se-, -P-, -CR1R2-, CR1, un groupe alkyle, NR3, et -C=O ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 12 chaînons ou un noyau hétérocyclique à 6 à 12 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 5 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C20, un groupe alkoxyle en C1-C10, un groupe polyalkoxyalkyle en C1-C10, un groupe polyhydroxyalkyle en C1-C20, un groupe polyhydroxyaryle en C5-C20, un groupe aminoalkyle en C1-C10, un groupe cyano, un groupe nitro, un halogène, un saccharide, un peptide, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, , -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -(CH2)-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-OH, et -(CH2)-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif, une protéine, une cellule, un anticorps, un fragment d'anticorps, un saccharide, un glycopeptide, un peptidomimétique, un médicament, un mimétique médicamenteux, une hormone, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif, et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 20 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 100.
  2. Composé selon la revendication 1, dans lequel W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -C(CH3)2, -C((CH2)aOH)CH3, -C((CH2)aOH)2, -C((CH2)aCO2H)CH3, -C((CH2)aCO2H)2, -C((CH2)aNH2)CH3, C((CH2)aNH2)2, C((CH2)aNR3R4)2, -NR3, et -S- ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi -O-, -S-, NR3, (CH2)a-CR1R2, et -CR1 ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 10 chaînons ou un noyau hétérocyclique à 6 à 10 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 3 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C12, un groupe alkoxyle en C1-C10, un groupe polyhydroxyalkyle en C1-C10, un groupe polyhydroxyaryle en C5-C12, un groupe aminoalkyle en C1-C10, un mono- ou un oligosaccharide, un peptide comprenant de 2 à 30 unités d'acides aminés, -CH2(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, (CH2)a-OH, et -CH2-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif comportant de 2 à 30 unités d'acides aminés, un anticorps, un mono- ou un oligosaccharide, un glycopeptide, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif, et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 10 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 30.
  3. Composé selon la revendication 2, dans lequel W3 et X3 correspondent chacun à C((CH2)OH)2 ; Y3 correspond à -(CH2)2-CONH-Bm ; Z3 correspond à -(CH2)2-CONH-Dm ; A1 correspond à une simple liaison ; A1, B1, C1 et D1 forment ensemble un noyau carbocyclique à 6 chaînons ; a3 et b3 correspondent chacun à 1 ; R29 correspond au galactose ; R30 à R37 correspondent chacun à l'hydrogène ; Bm correspond à l'octréotate ; et Dm correspond à la bombésine.
  4. Composition utilisable dans le cadre d'une procédure diagnostique ou thérapeutique, ladite composition comprenant
    une quantité efficace d'un composé de formule
    Figure imgb0022
     où W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -CR1R2, -O-, -NR3, -S-, et -Se; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-N(R3)-(CH2)b-CONH-Bm, (CH2)a-N(R3)-(CH2)c-NHCO-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, -(CH2)a-N(R3)-(CH2)b-CONH-Dm, (CH2)a-N(R3)-(CH2)c-NHCO-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3) CH2-(CH2OCH2)d-CONH-Dm, -CH2(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4 ; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres; parmi - O-, -S-, -Se-, -P-, -CR1R2-, CR1, un groupe alkyle, NR3, et -C=O ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 12 chaînons ou un noyau hétérocyclique à 6 à 12 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 5 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C20, un groupe alkoxyle en C1-C10, un groupe polyalkoxyalkyle en C1-C10, un groupe polyhydroxyalkyle en C1-C20, un groupe polyhydroxyaryle en C5-C20, un groupe aminoalkyle en C1-C10, un groupe cyano, un groupe nitro, un halogène, un saccharide, un peptide, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -(CH2)-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-OH, et -(CH2)-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif, une protéine, une cellule, un anticorps, un fragment d'anticorps, un saccharide, un glycopeptide, un peptidomimétique, un médicament, un mimétique médicamenteux, une hormone, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 20 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 100, ainsi qu'un support ou un excipient, acceptable sur le plan pharmaceutique, en vue de la fabrication d'une composition,
    l'activation du composé au moyen de lumière, et
    la mise en oeuvre de la procédure diagnostique ou thérapeutique.
  5. Composition selon la revendication 4, dans laquelle W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -C(CH3)2, -C((CH2)aOH)CH3, -C((CH2)aOH)2, -C((CH2)aCO2H)CH3, -C((CH2)aCO2H)2, -C((CH2)aNH2)CH3, C((CH2)aNH2)2, C((CH2)aNR3R4)2, -NR3, et -S- ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, - CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4 ; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi -O-, -S-, NR3, (CH2)a -CR1R2, et -CR1 ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 10 chaînons ou un noyau hétérocyclique à 6 à 10 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 3 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C12, un groupe alkoxyle en C1-C10, un groupe polyhydroxyalkyle en C1-C10, un groupe polyhydroxyaryle en C5-C12, un groupe aminoalkyle en C1-C10, un mono- ou un oligosaccharide, un peptide comportant de 2 à 30 unités d'acides aminés, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, (CH2)a-OH, et -CH2-(CH2OCH2)b-CO2H; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif comportant de 2 à 30 unités d'acides aminés, un anticorps, un mono- ou un oligosaccharide, un glycopeptide, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif, et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 10 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 30.
  6. Composition selon la revendication 5, dans laquelle W3 et X3 correspondent chacun à C((CH2)OH)2 ; Y3 correspond à -(CH2)2-CONH-Bm ; Z3 correspond à -(CH2)2-CONH-Dm ; A1 correspond à une simple liaison ; A1, B1, C1 et D1 forment ensemble un noyau carbocyclique à 6 chaînons ; a3 et b3 correspondent chacun à 1 ; R29 correspond au galactose ; R30 à R37 correspondent chacun à l'hydrogène ; Bm correspond à l'octréotate ; et Dm correspond à la bombésine (7-14).
  7. Composition selon l'une quelconque des revendications 4 à 6, ladite procédure utilisant une lumière d'une longueur d'onde de l'ordre de 350 à 1 300 nm.
  8. Composition selon l'une quelconque des revendications 4 à 7, la procédure diagnostique correspondant à la tomographie optique.
  9. Composition selon l'une quelconque des revendications 4 à 7, la procédure diagnostique correspondant à l'endoscopie par fluorescence.
  10. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure comprenant, en outre, l'étude du profil de la clairance sanguine dudit composé par un procédé choisi parmi la fluorescence, l'absorbance, et la diffusion de la lumière, une lumière d'une longueur d'onde de l'ordre de 350 à 1 300 nm étant utilisée.
  11. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure comprenant, en outre, une procédure d'imagerie et une procédure thérapeutique, lesdites procédures d'imagerie et thérapeutique étant choisies parmi l'absorption, la diffusion de la lumière, la technique photoacoustique et la technique de sonofluorescence.
  12. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure permettant de déceler la présence de plaques d'athérosclérose et de caillots sanguins.
  13. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure comprenant l'administration d'un traitement localisé.
  14. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure thérapeutique comprenant un traitement photodynamique.
  15. Composition selon l'une quelconque des revendications 4 à 7, ladite procédure thérapeutique comprenant de la chirurgie à guidage laser pour la détection de micrométastases.
  16. Composition selon l'une quelconque des revendications 4 à 15, comprenant, en outre, l'addition à la composition d'un solvant organique biocompatible à une concentration de un à cinquante pour cent afin de prévenir l'auto-extinction de la fluorescence in vivo ou in vitro.
  17. Composition selon la revendication 16, dans laquelle ledit composé est dissous dans un milieu comprenant de un à cinquante pour cent de diméthylsulfoxyde.
  18. Composition comprenant un bioconjugué de type colorant à base de cyanine de formule
    Figure imgb0023
     où W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -CR1R2, -O-, -NR3, - S-, et -Se ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-N(R3)-(CH2)b-CONH-Bm, (CH2)a-N(R3)-(CH2)c-NHCO-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, -(CH2)a-N(R3)-(CH2)b-CONH-Dm, (CH2)a-N(R3)-(CH2)c-NHCO-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Dm, -CH2(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4 ; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi - O-, -S-, -Se-, -P-, -CR1R2-, -CR1, un groupe alkyle, NR3, et -C=O ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 12 chaînons ou un noyau hétérocyclique à 6 à 12 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 5 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C20, un groupe alkoxyle en C1-C10, un groupe polyalkoxyalkyle en C1-C10, un groupe polyhydroxyalkyle en C1-C20, un groupe polyhydroxyaryle en C5-C20, un groupe aminoalkyle en C1-C10, un groupe cyano, un groupe nitro, un halogène, un saccharide, un peptide, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -(CH2)-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-OH, et -(CH2)-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif, une protéine, une cellule, un anticorps, un fragment d'anticorps, un saccharide, un glycopeptide, un peptidomimétique, un médicament, un mimétique médicamenteux, une hormone, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 20 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 100, ainsi qu'un support ou un excipient acceptable sur le plan pharmaceutique.
  19. Composition selon la revendication 18, dans laquelle W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -C(CH3)2, -C((CH2)aOH)CH3, -C((CH2)aOH)2, -C((CH2)aCO2H)CH3, -C((CH2)aCO2H)2, -C((CH2)aNH2)CH3, C((CH2)aNH2)2, C((CH2)aNR3R4)2, -NR3, et -S- ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, et -CH2(CH2OCH2)b-CH2NR3R4; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, et -CH2(CH2OCH2)b-CH2NR3R4 ; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi - O-, -S-, NR3, (CH2)a-CR1R2, et -CR1 ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 10 chaînons ou un noyau hétérocyclique à 6 à 10 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre ; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 3 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C12, un groupe alkoxyle en C1-C10, un groupe polyhydroxyalkyle en C1-C10, un groupe polyhydroxyaryle en C5-C12, un groupe aminoalkyle en C1-C10, un mono- ou un oligosaccharide, un peptide comportant de 2 à 30 unités d'acides aminés, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-OH, et -CH2-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif comportant de 2 à 30 unités d'acides aminés, un anticorps, un mono- ou un oligosaccharide, un glycopeptide, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif, et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 10 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 30.
  20. Composition selon la revendication 19, dans laquelle W3 et X3 correspondent chacun à C((CH2)OH)2; Y3 correspond à -(CH2)2-CONH-Bm; Z3 correspond à -(CH2)2-CONH-Dm ; A1 correspond à une simple liaison ; A1, B1, C1 et D1 forment ensemble un noyau carbocyclique à 6 chaînons ; a3 et b3 correspondent chacun à 1 ; R29 correspond au galactose ; R30 à R37 correspondent chacun à l'hydrogène ; Bm correspond à l'octréotate ; et Dm correspond à la bombésine (7-14).
  21. Composition comprenant un composé de formule
    Figure imgb0024
     où W3 et X3 sont choisis, indépendamment l'un de l'autre, parmi -CR1R2, -O-, -NR3, -S-, et -Se ; Y3 est choisi parmi -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, -(CH2)a-N(R3)-(CH2)b-CONH-Bm, (CH2)a-N(R3)-(CH2)c-NHCO-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Bm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Bm, -(CH2)a-NR3R4, et -CH2(CH2OCH2)b-CH2NR3R4 ; Z3 est choisi parmi -(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-NHCO-Dm, -(CH2)a-N(R3)-(CH2)b-CONH-Dm, (CH2)a-N(R3)-(CH2)c-NHCO-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Dm, -CH2(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Dm, -(CH2)a-NR3R4, et -CH2(CH2OCH2)b-CH2NR3R4 ; A1 correspond à une simple ou à une double liaison ; B1, C1 et D1 sont choisis, indépendamment les uns des autres, parmi -O-, -S-, -Se-, -P-, -CR1R2, -CR1, un groupe alkyle, NR3, et -C=O ; A1, B1, C1 et D1 peuvent former ensemble un noyau carbocyclique à 6 à 12 chaînons ou un noyau hétérocyclique à 6 à 12 chaînons contenant, éventuellement, au moins un des atomes suivants : oxygène, azote ou soufre; a3 et b3 sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 0 à 5 ; R1 à R4, et R29 à R37 sont choisis, indépendamment les uns des autres, parmi l'hydrogène, un groupe alkyle en C1-C10, un groupe aryle en C5-C20, un groupe alkoxyle en C1-C10, un groupe polyalkoxyalkyle en C1-C10, un groupe polyhydroxyalkyle en C1-C20, un groupe polyhydroxyaryle en C5-C20, un groupe aminoalkyle en C1-C10, un groupe cyano, un groupe nitro, un halogène, un saccharide, un peptide, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CO2H, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -(CH2)-(CH2OCH2)b-CH2-NHCO-Bm, (CH2)a-OH et -(CH2)-(CH2OCH2)b-CO2H ; Bm et Dm sont choisis, indépendamment l'un de l'autre, parmi un peptide bioactif, une protéine, une cellule, un anticorps, un fragment d'anticorps, un saccharide, un glycopeptide, un peptidomimétique, un médicament, un mimétique médicamenteux, une hormone, un agent chélateur métallique, un complexe métallique radioactif ou non radioactif et un agent échogène ; a et c sont choisis, indépendamment l'un de l'autre, parmi les nombres entiers de 1 à 20 ; et b et d sont choisis, indépendamment l'un de l'autre, parmi les nombres allant de 1 à 100, utilisable à des fins de visualisation et de détection des tumeurs.
EP01904882A 2000-01-18 2001-01-17 Colorants hydrophiles a base de cyanine Expired - Lifetime EP1250091B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US757332 1991-09-10
US09/484,319 US6180086B1 (en) 2000-01-18 2000-01-18 Hydrophilic cyanine dyes
US484319 2000-01-18
US09/757,332 US7011817B2 (en) 2000-01-18 2001-01-09 Hydrophilic cyanine dyes
PCT/US2001/001468 WO2001052744A1 (fr) 2000-01-18 2001-01-17 Colorants hydrophiles a base de cyanine

Publications (3)

Publication Number Publication Date
EP1250091A1 EP1250091A1 (fr) 2002-10-23
EP1250091A4 EP1250091A4 (fr) 2003-05-07
EP1250091B1 true EP1250091B1 (fr) 2008-04-16

Family

ID=27047953

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01904882A Expired - Lifetime EP1250091B1 (fr) 2000-01-18 2001-01-17 Colorants hydrophiles a base de cyanine

Country Status (5)

Country Link
EP (1) EP1250091B1 (fr)
JP (1) JP2003529632A (fr)
AT (1) ATE392183T1 (fr)
AU (1) AU2001232818A1 (fr)
WO (1) WO2001052744A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790144B2 (en) * 2000-01-18 2010-09-07 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
US6663847B1 (en) * 2000-10-13 2003-12-16 Mallinckrodt Inc. Dynamic organ function monitoring agents
US7556797B2 (en) 2000-10-16 2009-07-07 Mallinckrodt Inc. Minimally invasive physiological function monitoring agents
US6733744B1 (en) * 2000-10-16 2004-05-11 Mallinckrodt Inc. Indole compounds as minimally invasive physiological function monitoring agents
US20030105300A1 (en) * 2001-10-17 2003-06-05 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
US20030105299A1 (en) * 2001-10-17 2003-06-05 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
US20030152577A1 (en) * 2002-02-07 2003-08-14 Mallinckrodt Inc. Dye-bioconjugates for simultaneous optical diagnostic and therapeutic applications
US6919333B2 (en) * 2002-11-12 2005-07-19 Rutgers, The State University Of New Jersey Bis-transition-metal-chelate probes
EP1506402A2 (fr) * 2002-03-28 2005-02-16 Rutgers, The State University of New Jersey Sondes a chelates a deux metaux de transition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8615995D0 (en) * 1986-07-01 1986-08-06 Glaxo Group Ltd Veterinary preparations
DE3721850A1 (de) * 1987-07-02 1989-01-12 Bayer Ag Indolin-carbocyaninfarbstoffe
JP3354975B2 (ja) * 1992-10-06 2002-12-09 イビデン株式会社 蛍光標識試薬および蛍光免疫測定法
US5631364A (en) * 1994-03-31 1997-05-20 Axis Biochemicals Asa Labelled boronic acid derivatives
WO1996000902A1 (fr) * 1994-06-30 1996-01-11 Biometric Imaging, Inc. Colorants a base de cyanine substitues par des ions n-heteroaromatiques et par des ions iminium, utilises comme marques fluorescentes
IT1276833B1 (it) * 1995-10-09 1997-11-03 Sorin Biomedica Cardio Spa Coloranti fluorescenti della famiglia della solfo benz e indocianina
CA2342602A1 (fr) * 1998-09-17 2000-03-30 Nippon Kayaku Kabushiki Kaisha Remedes pour photochimioterapie
DE19911102A1 (de) * 1999-03-12 2000-09-14 Few Chemicals Gmbh Wolfen Cyanin-Farbstoffe
JP4041613B2 (ja) * 1999-03-12 2008-01-30 富士フイルム株式会社 画像形成材料
US6180086B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes

Also Published As

Publication number Publication date
WO2001052744A1 (fr) 2001-07-26
EP1250091A4 (fr) 2003-05-07
AU2001232818A1 (en) 2001-07-31
EP1250091A1 (fr) 2002-10-23
ATE392183T1 (de) 2008-05-15
JP2003529632A (ja) 2003-10-07

Similar Documents

Publication Publication Date Title
US7011817B2 (en) Hydrophilic cyanine dyes
US6641798B2 (en) Tumor-targeted optical contrast agents
US6706254B2 (en) Receptor-avid exogenous optical contrast and therapeutic agents
US7514069B2 (en) Tumor-targeted optical contrast agents
US7504087B2 (en) Receptor-avid exogenous optical contrast and therapeutic agents
US6761878B2 (en) Pathological tissue detection and treatment employing targeted benzoindole optical agents
EP1178830B1 (fr) Nouveaux bioconjugues cyanine et indocyanine pour application medicale
US6180085B1 (en) Dyes
EP1250095B1 (fr) Colorants hydrophiles versatiles
US6183726B1 (en) Versatile hydrophilic dyes
US6190641B1 (en) Indocyanine dyes
US20100022449A1 (en) Receptor-avid exogenous optical contrast and therapeutic agents
US20080233050A1 (en) Diagnostic and therapeutic optical agents
EP1250091B1 (fr) Colorants hydrophiles a base de cyanine
EP2201897A2 (fr) Agents photodiagnostics-photothérapeutiques ciblés de tumeur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAJAGOPALAN, RAGHAVAN

Inventor name: DORSHOW, RICHARD, B.

Inventor name: BUGAJ, JOSEPH, E.

Inventor name: ACHILEFU, SAMUEL, I.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61B 8/00 B

Ipc: 7A 61B 10/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030326

17Q First examination report despatched

Effective date: 20070523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60133626

Country of ref document: DE

Date of ref document: 20080529

Kind code of ref document: P

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080916

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2305054

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

26N No opposition filed

Effective date: 20090119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090117

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110301

Year of fee payment: 11

Ref country code: IT

Payment date: 20110125

Year of fee payment: 11

Ref country code: DE

Payment date: 20110127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110125

Year of fee payment: 11

Ref country code: ES

Payment date: 20110126

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080416

REG Reference to a national code

Ref country code: FR

Ref legal event code: CJ

Effective date: 20111116

Ref country code: FR

Ref legal event code: CA

Effective date: 20111116

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: MALLINCKRODT LLC

Effective date: 20120207

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60133626

Country of ref document: DE

Owner name: MALLINCKRODT LLC (N.D.GES.D.STAATES DELAWARE),, US

Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, MO., US

Effective date: 20120621

Ref country code: DE

Ref legal event code: R081

Ref document number: 60133626

Country of ref document: DE

Owner name: MALLINCKRODT LLC (N.D.GES.D.STAATES DELAWARE), US

Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, US

Effective date: 20120621

Ref country code: DE

Ref legal event code: R082

Ref document number: 60133626

Country of ref document: DE

Representative=s name: WINTER, BRANDL, FUERNISS, HUEBNER, ROESS, KAIS, DE

Effective date: 20120621

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120117

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120117

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60133626

Country of ref document: DE

Effective date: 20120801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120118